Triangulating molecular evidence to prioritise candidate causal genes at established atopic dermatitis loci - Sobczyk, Maria K; Richardson, Tom G; Zuber, Verena; Min, Josine L; eQTLGen Consortium; BIOS Consortium; GoDMC; Gaunt, Tom R; Paternoster, Lavinia (medRxiv, 2020)
Background Genome-wide association studies for atopic dermatitis (AD, eczema) have identified 25 reproducible loci associated in populations of European descent. We attempt to prioritise candidate causal genes at these loci using a multifaceted bioinformatic approach and extensive molecular resources compiled into a novel pipeline: ADGAPP (Atopic Dermatitis GWAS Annotation & Prioritisation Pipeline).Methods We identified a comprehensive list of 103 accessible molecular resources for AD aetiology, including expression, protein and DNA methylation QTL datasets in skin or immune-relevant tissues. These were used to test for overlap with GWAS signals (including colocalisation testing where possible). This was combined with functional annotation based on regulatory variant prediction, and independent genomic features such as chromatin accessibility, promoter-enhancer interactions, splicing sites, non-coding RNA regions, differential expression studies involving eczema patients and fine-mapping of causal variants. For each gene at each locus, we condensed the evidence into a prioritisation score.Results Across the 25 AD loci investigated, we detected significant enrichment of genes with adaptive immune regulatory function and epidermal barrier formation among the top prioritised genes. At 8 loci, we were able to prioritise a single candidate gene (IL6R, ADO, PRR5L, IL7R, ETS1, INPP5D, MDM1, TRAF3). At a further 2 loci, 2 candidate genes emerge (IL18R1/IL18RAP, LRRC32/EMSY). For the majority of these, the prioritised gene has been previously proposed as a plausible candidate, but the evidence we combine here, strengthens the case for many of these. In addition, at 6 of the 25 loci, our ADGAPP analysis prioritises novel alternative candidates (SLC22A5, IL2RA, MDM1, DEXI, ADO, STMN3), highlighting the importance of this comprehensive approach.Conclusions Our ADGAPP analysis provides additional support for previously implicated genes at several AD GWAS loci, as well as evidence for plausible novel candidates at others. We highlight several genes with good/converging evidence of involvement in AD that represent potential new targets for drug discovery.Competing Interest StatementTRG receives funding from GlaxoSmithKline and Biogen for unrelated research.Funding StatementThis work was supported by a Springboard award (SBF003\1094), awarded to LP, supported by the Academy of Sciences (AMS), the Wellcome Trust, the Government Department of Business, Energy and Industrial Strategy (BEIS) and the British Heart Foundation (BHF). TRG acknowledges support from the UK Medical Research Council (MC_UU_00011/4). TGR is a UKRI Innovation research fellow (MR/S003886/1). TwinsUK is funded by the Wellcome Trust, Medical Research Council, European Union, Chronic Disease Research Foundation (CDRF), Zoe Global Ltd and the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethics approval was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the code written to carry out the ADGAPP analysis is available on GitHub at: https://github.com/MRCIEU/eczema_gwas_fu Code is archived under: https://doi.org/10.5281/zenodo.3775865 The datasets supporting the conclusions of this article are available in the Figshare repository. https://doi.org/10.5281/zenodo.3775865 https://doi.org/10.6084/m9.figshare.12222731 https://doi.org/10.6084/m9.figshare.12130701 https://doi.org/10.6084/m9.figshare.12221006 https://doi.org/10.6084/m9.figshare.12221033 https://doi.org/10.6084/m9.figshare.12130824 https://doi.org/10.6084/m9.figshare.12130857 https://doi.org/10.6084/m9.figshare.12130863 https://doi.org/10.6084/m9.figshare.12130878